BenzingaAugust 6, 2026 at 10:20 AM NY2 Months Ago
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46
Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $46.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
